What Makes BioMarin (BMRN) so Attractive
As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 6,686,916 | $395,196,725 | +13% | 0.21% |
| 2. | Viking Global Andreas Halvorsen | 6,036,936 | $358,775,106 | -28% | 0.95% |
| 3. | Millennium Management Israel Englander | 3,037,616 | $180,525,519 | +16% | 0.08% |
| 4. | Vestal Point Capital Ryan Wilder | 3,000,000 | $178,290,000 | +262% | 6.06% |
| 5. | Deep Track Capital David Kroin | 2,300,000 | $136,689,000 | +9154% | 2.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.31 | 1,786 | $105,927.66 | 14,173 | 2025-05-20 | Filing | |
| $64.92 | 273 | $17,723.16 | 32,700 | 2025-05-02 | Filing | |
| $71.52 | 1,295 | $92,618.40 | 16,955 | 2025-03-19 | Filing | |
| $71.28 | 7,034 | $501,355.38 | 87,655 | 2025-03-06 | Filing | |
| $68.38 | 1,344 | $91,902.72 | 13,105 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,135,108 | $1,137,199,439 | 0.02% | |
| 2. | 18,127,847 | $1,077,337,946 | 0.02% | |
| 3. | 14,572,384 | $866,036,781 | 0.47% | |
| 4. | 14,549,314 | $864,665,732 | 0.65% | |
| 5. | 7,531,080 | $447,572,084 | 0.05% |
News See All
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks to buy now. Piper Sandler revised the price target on BioMarin Pharmaceutical Inc.
13 Most Promising Future Stocks to Buy Now
On February 6, Josh Belton, Gabelli Funds portfolio manager for growth equities, appeared on CNBC’s 'Squawk Box' to talk about the latest market trends, his perspective on where AI is generating revenue...
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays
Barclays initiated coverage of BioMarin on January 28, assigning it an “Overweight” rating and a target price of $80. This target price implies a 41.5% upside from the current price.
12 Best Cheap Stocks to Buy Right Now
Kevin Warsh, Donald Trump’s pick to be the next chair of the Federal Reserve, could be good news for the stock market, at least in the near term.
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN)
On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy.
15 Large Cap Stocks Under $100 With Huge Upside Potential
The large-cap stock universe comprises mature companies with market capitalizations ranging between $10 billion and $200 billion.
10 Cheap Stocks with Huge Upside Potential
We’re only one month into 2026, and the progress of global economies has been anything but normal.
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C.
Hedge Fund Resource Center Billionaire Hedge Funds
